Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf

Oncogene

Volumn 26, Issue 6, 2007, Pages 813-821

  Marzec, M ^a   Kasprzycka, M ^a   Liu, X ^a   Raghunath, P N ^a   Wlodarski, P ^a   Wasik, M A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

MEK ERK pathway; NPM ALK tyrosine kinase; T cell lymphoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYCLIN DEPENDENT KINASE 4; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; NUCLEOPHOSMIN; PROTEIN; PROTEIN BCL XL; PROTEIN C RAF; SMALL INTERFERING RNA; TYROSINE KINASE ALK; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; FUNCTIONAL PROTEOMICS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

CELL PROLIFERATION; CELLS, CULTURED; ENZYME ACTIVATION; GENE DELETION; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 33846951463     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209843     Document Type: Article

References (34)

1. Bischof D, Pulford K, Mason DY, Morris SW. (1997). Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 2312-2325.
2. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J et al. (2003). NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101: 1919-1927.
3. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. (2005). Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11: 623-629.
4. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. (2004). Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 23: 2617-2629.
5. Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N et al. (2004). ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 23: 9220-9229.
6. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S et al. (1996). Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 93: 4181-4186.
7. Hallek M, Bergsagel PL, Anderson KC. (1998). Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3-21.
8. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
9. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822.
10. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M et al. (2000). Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 14: 642-656.
11. Kim SC, Hahn JS, Min YH, Yoo NC, Ko YW, Lee WJ. (1999). Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 93: 3893-3899.
12. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY et al. (1997). Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90: 2901-2910.
13. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N et al. (2005). Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85: 1544-1554.
14. Matsumoto S, Miyagishi M, Akashi H, Nagai R, Taira K. (2005). Analysis of double-stranded RNA-induced apoptosis pathways using interferon-response noninducible small interfering RNA expression vector library. Biol Chem 280: 25687-25696.
15. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. (2001). Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108: 851-859.
16. Morgan MA, Dolp O, Reuter CW. (2001). Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97: 1823-1834.
17. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
18. Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T. (2004). ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 117: 3319-3329.
19. Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ. (2002). Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 277: 12040-12046.
20. Platanias LC. (2003). Map kinase signaling pathways and hematologic malignancies. Blood 101: 4667-4679.
21. Pratt G. (2002). Molecular aspects of multiple myeloma. Mol Pathol 55: 273-283.
22. Roux PP, Blenis J. (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344.
23. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. (1994). Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9: 1567-1574.
24. Souttou B, Carvalho NB, Raulais D, Vigny M. (2001). Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 276: 9526-9531.
25. Tanaka T, Kyrokawa M, Ueki K, Tanaka K, Imai Y, Mitani K et al. (1996). The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 16: 3967-3979.
26. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H. (1997). Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 11: 479-484.
27. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. (1996). Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 271: 23512-23519.
28. Ussar S, Voss T. (2004). MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem 279: 43861-43869.
29. Wan W, Albom MS, Lu L, Quail MR, Becknell NC, Weinberg LR et al. (2006). Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107: 1617-1623.
30. Wang X, Wang Q, Hu W, Evers BM. (2004). Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway. Oncogene 23: 1885-1895.
31. Wasik MA. (2002). Expression of anaplastic lymphoma kinase in non-Hodgkin's lymphomas and other malignant neoplasms. Biological, diagnostic, and clinical implications. Am J Clin Pathol 118: S81-S92.
32. Wen-Sheng W. (2006). Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Cancer Lett 239: 27-35.
33. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A et al. (2005). Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65: 7800-7808.
34. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N et al. (2002). Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168: 466-474.